Loading cancer entity…
Loading cancer entity…
Clinical trials
59 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (5)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06462222 | Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 45 | Guangzhou Medical UniversityOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07833657 | Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan for Leptomeningeal Metastases(ITST-ADC-LM) | not yet recruiting | Phase 2 | 28 | Jiuda ZhaoOTHER | 1 | Sep 22, 2026 |
| clinicaltrials |
| NCT06762080 | Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis | active not recruiting | Phase 1 / Phase 2 | 36 | Guangzhou Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06809530 | Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis | active not recruiting | Phase 1 / Phase 2 | 34 | Guangzhou Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07778940 | Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.(LEP-THP-2026) | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06812871 | High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis | completed | Phase 2 | 46 | Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07551414 | Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI | not yet recruiting | Phase 2 | 38 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05805631 | Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | recruiting | Phase 2 | 23 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04343573 | Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors | completed | Phase 2 | 102 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07264569 | Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 | recruiting | Phase 1 / Phase 2 | 42 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT01373710 | Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis(HIT) | completed | Phase 1 / Phase 2 | 34 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT02939300 | Ipilimumab and Nivolumab in Leptomeningeal Metastases | completed | Phase 2 | 18 | Massachusetts General HospitalOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04729348 | Pembrolizumab And Lenvatinib In Leptomeningeal Metastases | terminated | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06809517 | Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis | recruiting | Phase 1 / Phase 2 | 34 | Guangzhou Medical UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06971406 | High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis(FLAME-1) | not yet recruiting | Phase 2 | 100 | Qiming WangOTHER_GOV | 0 | May 14, 2025 | clinicaltrials |
| NCT05289908 | Intrathecal Pemetrexed for Leptomeningeal Metastasis | completed | Phase 1 / Phase 2 | 34 | The First Hospital of Jilin UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT06901817 | A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases | recruiting | Phase 2 | 97 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06861218 | Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases | not yet recruiting | Phase 2 | 42 | Zhejiang Cancer HospitalOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06441045 | Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI | not yet recruiting | Phase 2 | 112 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 4, 2024 | clinicaltrials |
| NCT04315246 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) | withdrawn | Phase 1 / Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 2 | Jul 15, 2022 | clinicaltrials |
| NCT05385185 | Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer | unknown | Phase 2 | 20 | Hebei Medical UniversityOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT04425681 | Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer(OWBLM) | unknown | Phase 2 | 20 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03507244 | Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors | completed | Phase 1 / Phase 2 | 34 | The First Hospital of Jilin UniversityOTHER | 1 | Dec 26, 2019 | clinicaltrials |
| NCT04148898 | Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis(OWONBNSCLCLM) | unknown | Phase 2 | 80 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT03082144 | Concurrent Involved-field Radiotherapy and Intrathecal Chemotherapy for Leptomeningeal Metastases From Solid Tumors | completed | Phase 2 | 53 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT01818713 | Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases | unknown | Phase 2 | 6 | The Netherlands Cancer InstituteOTHER | 1 | Oct 29, 2013 | clinicaltrials |
| NCT00005812 | Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma | terminated | Phase 2 | 12 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 14, 2013 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials